CIP
ALXO icon

Chartwell Investment Partners’s ALX Oncology ALXO Stock Holding History

Chartwell Investment Partners’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5,290
Closed -$391K – 424
2021
Q3 		$391K Hold
5,290
– – 0.01% 421
2021
Q2 		$289K Buy
5,290
+47
+0.9% +$2.81K 0.01% 421
2021
Q1 		$387K Sell
5,243
-281
-5% -$22.1K 0.01% 408
2020
Q4 		$476K Buy
+5,524
New +$332K 0.02% 405

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Chartwell Investment Partners's ALXO Position: Q4 2021 in Review

Chartwell Investment Partners sold out of ALX Oncology (ALXO) in Q4 2021, closing a stake of 5,290 shares — an estimated $391K sold.

Chartwell Investment Partners first reported a position in ALXO in Q4 2020 and held it in 4 quarters. The position peaked at $476K in Q4 2020. 108 funds tracked by Wall St. Rank hold ALXO as of Q4 2021.

  • Chartwell Investment Partners reported no remaining ALX Oncology position as of Q4 2021 after selling out during the quarter.
  • Chartwell Investment Partners sold 5,290 ALX Oncology shares in Q4 2021, an estimated $391K.
  • Chartwell Investment Partners first reported a position in ALX Oncology in Q4 2020 and held it in 4 quarters.
  • Chartwell Investment Partners's ALX Oncology position peaked at $476K in Q4 2020.
  • 108 funds tracked by Wall St. Rank held ALX Oncology as of Q4 2021.

Based on Chartwell Investment Partners's 13F filing for Q4 2021, filed 15 Feb 2022.